Journal article
Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
Abstract
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an …
Authors
Ragon BK; Shah MV; D’Souza A; Estrada-Merly N; Gowda L; George G; de Lima M; Hashmi S; Kharfan-Dabaja MA; Majhail NS
Journal
Blood Advances, Vol. 7, No. 12, pp. 2746–2757
Publisher
American Society of Hematology
Publication Date
June 27, 2023
DOI
10.1182/bloodadvances.2022009138
ISSN
2473-9529